Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|December 1, 2019
- Pharmaceutical Executive-12-01-2019
- Volume 39
- Issue 12
Pharmaceutical Executive, December 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive December 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Market Access: Employers as Barriers to Valuealmost 7 years ago
Lundbeck's Taj Bhardwaj: Market Access and Mental Healthalmost 7 years ago
The Route to Market Access in Europealmost 7 years ago
A Multi-Stakeholder Perspective On Assessing Drug Valuealmost 7 years ago
When the Patient Loses in Market Accessalmost 7 years ago
Making Sense of Copay Accumulatorsalmost 7 years ago
Year in Review: R&D, Regulatory, and Reimbursement Hurdlesalmost 7 years ago
Who’s Going to Choose Where to Launch a Drug?almost 7 years ago
Back to the Basics?almost 7 years ago
Focus Report: Puerto RicoAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5